Clinical Trials Browser

Phase 2 × Lung Neoplasms × Imatinib Mesylate × Clear all

NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

NCT01011075 2015-07-03

6137p

Phase 2 Completed

34 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00323362 2014-05-22

Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 2 Terminated

17 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00425646 2013-05-06

Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

50 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00248482 2013-04-29

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2 Completed

6 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT00222144 2012-08-07

Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

23 enrolled

Thoracic

Lung Neoplasms

NCT01083589 2012-01-11

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

22 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00193349 2010-06-28

Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Phase 2 Completed

60 enrolled

Thoracic

Lung Neoplasms